Myelodysplastic Syndrome Clinical Trials
STUDY
CONDITIONS
INTERVENTIONS
LOCATIONS
LAST UPDATED
S
Recruiting
- Acute Myeloid Leukemia
- +14 more
- Fludarabine
- +7 more
- Philadelphia, PennsylvaniaThomas Jefferson University
2022-04-07
Apr 7, 2022P
Recruiting
- Acute Myeloid Leukemia
- +3 more
- Orlando, Florida
- +3 more
2022-03-31
Mar 31, 2022I
Recruiting
- Myelofibrosis
- +5 more
- Birmingham, Alabama
- +26 more
2022-03-30
Mar 30, 2022A
Recruiting
- Acute Myeloid Leukemia (AML)
- Myelodysplastic Syndrome
- ASP7517
- Duarte, California
- +18 more
2022-04-07
Apr 7, 2022N
Recruiting
- Myelodysplastic Syndrome
- +4 more
- Rituximab
- +6 more
- Bethesda, Maryland
- +1 more
2022-04-07
Apr 7, 2022N
Completed
- Acute Lymphoblastic Leukemia
- +5 more
- Radiation
- +3 more
- New Hyde Park, New YorkCohen Children's Medical Center
2022-04-06
Apr 6, 2022M
Not yet recruiting
- Myelodysplastic Syndrome
- RBC transfusion
- (no location specified)
2022-04-05
Apr 5, 2022C
Active, not recruiting
- Acute Myelogenous Leukemia
- Myelodysplastic Syndrome
- Emavusertib
- +2 more
- Tampa, Florida
- +8 more
2022-04-05
Apr 5, 2022M
Recruiting
- Acute Bilineal Leukemia
- +8 more
- Azacitidine
- +3 more
- Houston, TexasM D Anderson Cancer Center
2022-04-05
Apr 5, 2022N
Active, not recruiting
- Acute Myeloid Leukemia
- +2 more
- Azacitidine
- +5 more
- Anchorage, Alaska
- +506 more
2022-04-05
Apr 5, 2022N
Active, not recruiting
- Myelodysplastic Syndrome
- Entinostat
- Pembrolizumab
- New Haven, Connecticut
- +18 more
2022-04-05
Apr 5, 2022N
Completed
- Chronic Myelogenous Leukemia
- +9 more
- Fludarabine
- +3 more
- Atlanta, GeorgiaNorthside Hospital
2022-04-04
Apr 4, 2022F
Recruiting
- Acute Biphenotypic Leukemia
- +5 more
- Ex-Vivo Expanded Cord Blood Progenitor Cell Infusion
- +6 more
- Seattle, WashingtonFred Hutch/University of Washington Cancer Consortium
2022-03-31
Mar 31, 2022F
Recruiting
- Juvenile Myelomonocytic Leukemia
- +27 more
- CD8+ and CD4+ Donor Memory T-cells-expressing HA1-Specific TCR
- +2 more
- Seattle, WashingtonFred Hutch/University of Washington Cancer Consortium
2022-03-16
Mar 16, 2022R
RAD001 in Combination With PKC412 in Patients With Relapsed, Refractory or Poor Prognosis AML or MDS
Active, not recruiting
- Acute Myeloid Leukemia
- Myelodysplastic Syndrome
- Boston, Massachusetts
- +2 more
2022-03-28
Mar 28, 2022N
Not yet recruiting
- Myelodysplastic Syndrome
- +4 more
- UAE Inhibitor TAK-243
- (no location specified)
2022-03-25
Mar 25, 2022N
Completed
- Myeloproliferative Disorders
- +4 more
- T-cell replete PBPC allograft
- Bethesda, MarylandNational Institutes of Health Clinical Center, 9000 Rockville Pi
2022-03-24
Mar 24, 2022N
Recruiting
- Neoplasms
- +3 more
- Iowa City, Iowa
- +6 more
2022-03-24
Mar 24, 2022C
Recruiting
- Acute Myeloid Leukemia
- +5 more
- Decitabine
- +2 more
- Duarte, CaliforniaCity of Hope Comprehensive Cancer Center
2022-03-09
Mar 9, 2022P
Completed
- Myelodysplastic Syndrome
- +2 more
- PF-04449913 (Glasdegib)
- Azacitidine
- Birmingham, Alabama
- +32 more
2022-03-14
Mar 14, 2022F
Recruiting
- Acute Erythroid Leukemia
- +10 more
- Fludarabine
- +5 more
- San Francisco, California
- +4 more
2022-03-21
Mar 21, 2022C
Recruiting
- Acute Myeloid Leukemia
- +4 more
- Asparaginase
- +7 more
- Birmingham, Alabama
- +190 more
2022-03-21
Mar 21, 2022R
Recruiting
- Accelerated Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive
- +36 more
- Cyclophosphamide
- +4 more
- Buffalo, New YorkRoswell Park Cancer Institute
2022-03-17
Mar 17, 2022D
Active, not recruiting
- Myelodysplastic Syndrome
- +2 more
- GVAX
- +6 more
- Boston, Massachusetts
- +3 more
2022-02-23
Feb 23, 2022G
Completed
- Acute Myeloid Leukemia
- +3 more
- (no location specified)
2022-03-16
Mar 16, 2022